EP2099802A2 - Quinazolines substituées - Google Patents

Quinazolines substituées

Info

Publication number
EP2099802A2
EP2099802A2 EP07824909A EP07824909A EP2099802A2 EP 2099802 A2 EP2099802 A2 EP 2099802A2 EP 07824909 A EP07824909 A EP 07824909A EP 07824909 A EP07824909 A EP 07824909A EP 2099802 A2 EP2099802 A2 EP 2099802A2
Authority
EP
European Patent Office
Prior art keywords
compound
group
alkyl
cyano
optionally substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP07824909A
Other languages
German (de)
English (en)
Inventor
Richard Franklin
Bernard Golding
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shire LLC
Original Assignee
Shire LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shire LLC filed Critical Shire LLC
Publication of EP2099802A2 publication Critical patent/EP2099802A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Definitions

  • This invention relates to the discovery of 3-and 5-substituted analogues of the selective platelet lowering agent anagrelide with reduced potential for cardiovascular side-effects which should lead to improved patient compliance and safety in the treatment of myeloproliferative diseases. More specifically, the present invention relates to certain imidazoquinazoline derivatives which have utility as platelet lowering agents in humans.
  • the compounds of the present invention function by inhibiting megakaryocytopoeisis and hence the formation of blood platelets.
  • Anagrelide hydrochloride (Agrylin®, Xagrid®) is a novel orally administered imidazoquinazoline which selectively reduces platelet count in humans and is used for such purposes in the treatment of myeloproliferative diseases (MPDs), such as essential thrombocythemia (ET), where an elevated platelet count may put the patient at increased thrombotic risk.
  • MPDs myeloproliferative diseases
  • ET essential thrombocythemia
  • the chemical structure of anagrelide, 6,7-dichloro-l,5-dihydroimidazo[2,l-&]- quinazolin-2(3//)-one hydrochloride monohydrate is shown as the hydrochloride monohydrate in the following formula:
  • Anagrelide is a unique, highly selective platelet lowering agent. In vitro studies of human megakaryocytopoiesis suggested that, in vivo, its thrombocytopenic activity results primarily from an inhibitory effect on megakaryocyte maturation. Anagrelide inhibited TPO-induced megakaryocytopoiesis in a dose-dependent manner with an estimated IC 50 of -26 nM, showing it to be a highly potent agent. Anagrelide does not affect erythroid or myelomonocytic differentiation stimulated by erythropoietin or granulocyte-macrophage colony-stimulating factor, demonstrating the selectivity of this compound against the megakaryocytic lineage.
  • the drug which is available in both the U.S. and Europe, has proven to be of considerable clinical value in the treatment of myeloproliferative diseases, such as essential thrombocythemia.
  • Anagrelide was shown to be effective and selective in reducing and maintaining platelet count close to or within the physiological range in patients with thrombocythemia secondary to a myeloproliferative disorder.
  • the time to complete response defined as a platelet count ⁇ 600xl0 9 /L, ranged from 4 to 12 weeks. In the majority of patients, the platelet count can be reduced and maintained at a dose of 1 to 3mg/day.
  • Inhibition of myocardial PDE III leads to positive inotropy (increasing of the force of contractions of the heart), increased chronotropy (increase in heart rate), and peripheral vasodilatation.
  • Such cardiovascular manifestations of this inhibition are typically seen with the classical positive inotropes, milrinone and enoximone, and exploited in the short-term acute treatment of congestive heart failure.
  • a so-called silent disease i.e., asymptomatic
  • ET the cardiovascular side-effects of palpitations and tachycardia associated with anagrelide limit its utility and a significant proportion of patients - reportedly between 25 and 50% - fail to tolerate the drug during long term treatment.
  • the PDE III inhibitory properties of anagrelide are quite distinct from its platelet lowering anti- megakaryocytic effects. Indeed studies have shown no correlation between potency as a PDE III inhibitor and anti-megakaryocytic effects for anagrelide and its principal pharmacologically active metabolite, 3-hydroxyanagrelide (3-OH anagrelide or 3-HA, formerly known as SPD604 or BCH24426). Surprisingly the latter was found to be over 40-fold more potent than anagrelide as a PDE III inhibitor. With respect to inhibition of megakaryocytopoiesis (and therefore platelet lowering potential) it was however no more potent than the parent drug.
  • the PDE III mediated cardiovascular side-effects associated with anagrelide treatment mean that many patients have to be switched to the only significant alternative therapy, namely that with hydroxyurea.
  • this drug is a simple chemical anti-metabolite which inhibits ribonucleoside diphosphate reductase (RNR) with resultant profound effects on DNA synthesis.
  • RNR ribonucleoside diphosphate reductase
  • Ribonucleoside diphosphate reductase catalyzes the conversion of ribonucleosides into deoxyribonucleosides, which are the building blocks of DNA synthesis and repair.
  • hydroxyurea is thus officially classified as a "presumed human carcinogen.” As well as possessing the potential to induce leukemic transformation, hydroxyurea is associated with the induction of difficult-to-treat leg ulcers.
  • anagrelide generally proceeds extremely rapidly, resulting in a less than ideal pharmacokinetic profile of the drug.
  • the typical half-life of anagrelide is just 1.5 hr (2.5 hr for the metabolite) necessitating frequent drug administration (up to 4 times per day). This, combined with the side-effects profile, can lead to poor patient compliance.
  • anagrelide undergoes a large first pass effect (>50%) leading to considerable intersubject variation in achieved exposures and, therefore, potentially variable drug response.
  • exposure to the pharmacologically active metabolite varies dramatically between patients since its formation is dependent on CYPlA, an enzyme whose expression is highly dependent on exposure to inducing agents such as cigarette smoke. Overall, this may result in the need for careful dose titration in patients being treated with anagrelide.
  • US4256748 discloses a number of imidazo[2,l-b]quinazolin-2(3H)-ones which have an analogous structure to anagrelide and which are said to be effective in the treatment of thromboses resulting from their anti-aggregatory effects on blood platelets mediated by PDE III inhibition.
  • this disclosure does not appreciate the entirely separate anti- megakaryocytic potential (reducing platelet numbers) which could be associated with some analogues.
  • the compounds of the present invention should have an improved pharmacokinetic profile to aid patient compliance and ensure consistency of therapeutic response. It is thus a further aim to provide compounds with a good duration of action i.e. long half-life in vivo. Additionally it is a further aim to provide compounds that are available via relatively convenient synthetic processes.
  • analogues of anagrelide in which the principal site of metabolism is blocked by an appropriate group are likely not only to have improved pharmacokinetics but also a better side effect profile. This would be expected to lead to better tolerability and improved patient compliance enabling a broader spectrum of patients to be effectively treated.
  • the compounds of the present invention are surprisingly beneficial for two reasons: they have a dramatically lower PDE III inhibitory activity than 3-hydroxyanagrelide, yet still retain potent anti-megakaryocytic activity. Indeed these compounds have therapeutic indices which are likely to be much more favorable than that for anagrelide itself.
  • the present invention encompasses an anagrelide analogue comprising a 3-, 5-, 3,3- or 5,5-substituted anagrelide compound.
  • an anagrelide analogue comprising a 3-, 5-, 3,3- or 5,5-substituted anagrelide compound.
  • anagrelide analogues comprising 3-substituted derivatives, wherein first pass metabolism to the corresponding 3-hydroxyanagrelide is effectively blocked.
  • a bulky group is more effective than a smaller group.
  • Groups such as t-butyl and other bulky blocking groups are thus expected to be of most utility when substituted at the 5-position.
  • a substituent comprising a large group at the 5-position is expected to sterically hinder access to the 3-position by the metabolising cytochrome's active site. This should inhibit formation of the cardioactive metabolite, 3-hydroxyanagrelide.
  • R 1 , R 2 , R 3 and R 4 independently represent hydrogen or a blocking group which functions to directly or indirectly prevent metabolic reaction at the 3- position of substitution;
  • R 1 and R 2 , and/or R 3 and R 4 together with the carbon to which they are attached form a blocking group which functions to directly or indirectly prevent metabolic reaction at either the 3-position of substitution, the remainder of groups R 1 to R 4 being hydrogen;
  • R 5 is selected from the group comprising: fluoro, chloro, bromo and iodo;
  • R 6 is selected from the group comprising: fluoro, chloro, bromo and iodo;
  • R 7 and R 8 are independently selected from the group comprising: H; halo; cyano; C 1-6 alkyl, C 1-6 haloalkyl, C 1-6 alkoxy, and C 1-6 haloalkoxy; and
  • R 9 is H, C 1-6 alkyl, or a Group I metal ion
  • R 1 , R 2 , R 3 and R 4 are not all hydrogen, or that when one of R 1 and R 2 is methyl and R and R are hydrogen then other of R and R is not hydrogen.
  • R and R are independently selected from the group comprising: H; cyano; Ci_ 6 alkyl, SCi_ 6 alkyl, C 2 - 6 alkenyl, C 2 - 6 alkynyl, C 3 _ 8 cycloalkyl wherein said alkyl, alkenyl, alkynyl or cycloalkyl groups may be optionally substituted by 1 to 5 groups chosen independently from the group comprising: halo, hydroxyl, cyano, nitro, Ci_ 4 alkylsulphonyl and COOH; Ci_ 6 hydroxyalkyl; Ci_ 6 carboxyalkyl; and sulphide;
  • R and R together represent a C 2 -6 alkenyl or C 2 -6 alkynyl group bound through a double bond to the ring to which it is attached and which may be optionally substituted by one to three groups independently selected from the group comprising: halo, hydroxyl, cyano, Ci_ 4 haloalkyl and COOH.
  • R is an optionally substituted Ci_ 4 alkyl or C 3 _ 8 cycloalkyl group.
  • R 2 is an optionally substituted C 1 - 4 alkyl group or C 3 - 8 cycloalkyl.
  • R 1 and R 2 together form an optionally substituted C 3 - 8 cycloalkyl group. Most preferably this is a cyclopropyl group
  • R 1 and R 2 is CF 3 or CHF 2 . More preferably, at least one of R 1 and R 2 is CF 3 .
  • R is preferably methyl, cyclopropyl, CF 3 or CHF 2 . More preferably, R is methyl or cyclopropyl. Most preferably, R is methyl. In an embodiment, R is preferably methyl, cyclopropyl, CF 3 or CHF 2 . More preferably R is methyl or cyclopropyl. Most preferably R is methyl.
  • R and R are independently selected from the group comprising: H; cyano; Ci_ 6 alkyl, SCi_ 6 alkyl, C 2 -6 alkenyl, C 2 -6 alkynyl, C 3 -S cycloalkyl wherein said alkyl, alkenyl, alkynyl or cycloalkyl groups may be optionally substituted by 1 to 5 groups chosen independently from the group comprising: halo, hydroxyl, cyano, nitro, Ci_ 4 alkylsulphonyl and COOH; Ci_ 6 hydroxyalkyl; Ci_ 6 carboxyalkyl; and sulphide;
  • R and R together represent a C 2 -6 alkenyl or C 2 -6 alkynyl group bound through a double bond to the ring to which it is attached and which may be optionally substituted by one to three groups independently selected from the group comprising: halo, hydroxyl, cyano, C 1 - 4 haloalkyl and COOH.
  • R 3 is H or C 1-6 alkyl. Preferably, R 3 is H.
  • R 4 is H or C 1-6 alkyl. Preferably, R 4 is H.
  • R is preferably chloro
  • R 6 is preferably chloro.
  • R is H.
  • R is H.
  • R is H.
  • R is Ci_ 6 alkyl and, in this case, the PDE III inhibiting activity is effectively eliminated.
  • Me represents a particularly preferred alkyl substituent.
  • R is a Group I metal ion and, in this case the compounds show significantly improved water solubility.
  • Sodium represents a particularly preferred Group I metal.
  • R and R are independently selected from the group comprising: H; cyano; Ci_ 6 alkyl, C 2 - 6 alkenyl, C 2 - 6 alkynyl, C 3 - S cycloalkyl wherein said alkyl, alkenyl, alkynyl or cycloalkyl groups may be optionally substituted by 1 to 5 groups chosen independently from the group comprising: halo, hydroxyl, cyano, nitro, Ci_ 4 alkylsulphonyl and COOH; Ci_ 6 hydroxyalkyl; Ci_ 6 carboxyalkyl; and sulphide; or R 1 and R 2 together with the carbon to which they are attached form a C 3 - 8 carbocyclic ring may be optionally substituted by 1 to 5 groups chosen independently from the group comprising: halo, hydroxyl, cyano, nitro, C 1 - 4 haloalkyl, C 1 - 4 alkylsulphonyl and COOH;
  • R 1 and R 2 together with the carbon to which they are attached represent a C 2 -6 alkenyl or C 2 -6 alkynyl group bound through a double bond to the ring to which it is attached and being optionally substituted by one to three groups independently selected from the group comprising: halo, hydroxyl, cyano, C 1 - 4 haloalkyl and COOH;
  • R 1 and R 2 are not both hydrogen, or that when one of R 1 and R 2 is methyl the other is not hydrogen;
  • R and R are hydrogen
  • R is selected from the group comprising: fluoro, chloro, bromo and iodo;
  • R is selected from the group comprising: fluoro, chloro, bromo and iodo;
  • R , R and R are hydrogen ⁇
  • R and R are both independently selected from the group comprising: cyano, Ci_6 alkyl, C 2 -6 alkenyl, C 2 -6 alkynyl, in which the alkyl, alkenyl, and alkynyl groups may be optionally substituted;
  • R 1 and R 2 together represent an optionally substituted C 2 - 6 alkenyl or C 2 - 6 alkynyl group.
  • Particularly preferred individual compounds of the invention include:
  • Particularly preferred compounds include 3,3-dimethylanagrelide, ⁇ spiro[anagrelide-3,l'- cyclopropane] ⁇ . These compounds are generally prepared as the HBr addition salts.
  • the present invention therefore also relates to both the resolved optical isomers of such compounds as well as mixtures of enantiomers.
  • the correct comparison is that made with the PDE III inhibitory activity of the 3-hydroxy metabolite of anagrelide since this is the predominant component in plasma after anagrelide treatment.
  • composition comprising a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, together with a pharmaceutically acceptable diluent or carrier, which may be adapted for oral, parenteral or topical administration;
  • a method of treating a disease selected from: myeloproliferative diseases and/or generalised thrombotic diseases in a human which comprises treating said human with an effective amount of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, or with a pharmaceutical composition containing any of the foregoing.
  • the present invention also encompasses a method of treating a patient having essential thrombocythemia or high blood platelet count, which method comprises administering to the patient a therapeutically effective amount of a compound of the present invention.
  • Another embodiment of the present invention includes a method of reducing blood platelet count within a patient, which method comprises administering to the patient a therapeutically effective amount of a compound of the present invention.
  • the present invention encompasses providing the compounds of the present invention for the methods listed above, among others, wherein cardiotoxicity is reduced compared to using anagrelide.
  • the invention also includes the use of 3-methyl anagrelide, or a pharmaceutically acceptable salt or solvate thereof in the manufacture of a medicament for the treatment of myeloprolific diseases.
  • the invention thus also extends to a method of treating myeloproliferative diseases in a human, which comprises treating said human with an effective amount of 3-methyl anagrelide, or a pharmaceutically acceptable salt or solvate thereof, or with a pharmaceutical composition containing any of the foregoing.
  • the present invention also encompasses pharmaceutical compositions comprising a compound or pharmaceutically acceptable salt of a compound of the present invention and a pharmaceutically acceptable carrier.
  • the present invention is directed to new 3 or 5-substituted analogues of the established platelet lowering agent anagrelide. Substitution at the 3 or the adjacent 5-position of the anagrelide molecule would be expected to block or hinder the principal site of metabolism and potentially preclude the formation of the highly potent PDE III inhibitor 3 -OH anagrelide while substitution at the 1 -position has surprisingly been found to abolish PDE III inhibition.
  • the compounds of the present invention retain the anti-megakaryocytic properties (hence platelet lowering activity) of the parent drug molecule but have reduced PDE III inhibitory properties and hence lower potential for unwanted cardiovascular and anti-aggregatory side-effects. They also have the potential for improved pharmacokinetic characteristics as the result of inhibition of metabolism.
  • the pharmaceutically acceptable acid addition salts of certain of the compounds of formula (I) may also be prepared in a conventional manner. For example, a solution of the free base is treated with the appropriate acid, either neat or in a suitable solvent, and the resulting salt isolated either by filtration or by evaporation under reduced pressure of the reaction solvent.
  • suitable salts see "Handbook of Pharmaceutical Salts: Properties, Selection, and Use” by Stahl and Wermuth (Wiley- VCH, Weinheim, Germany, 2002).
  • Halo means a group selected from: fluoro, chloro, bromo or iodo.
  • alkyl as used herein as a group or a part of a group refers to a straight or branched hydrocarbon chain containing the specified number of carbon atoms.
  • C 1 10 alkyl means a straight or branched alkyl containing at least 1 and at most 10 carbon atoms.
  • alkyl as used herein include, but are not limited to, methyl, ethyl, n-propyl, n-butyl, n- pentyl, isobutyl, isopropyl, t-butyl, hexyl, heptyl, octyl, nonyl and decyl.
  • a C ⁇ alkyl group is one embodiment, for example methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl or t-butyl.
  • cycloalkyl refers to a non-aromatic monocyclic hydrocarbon ring of 3 to 8 carbon atoms such as, for example, but not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or cycloheptyl.
  • spirocyclic refers to a ring system joined to a second ring system at one carbon atom.
  • alkoxy refers to a straight or branched hydrocarbon chain group containing oxygen and the specified number of carbon atoms.
  • C 1 6 alkoxy means a straight or branched alkoxy containing at least 1 and at most 6 carbon atoms.
  • alkoxy as used herein include, but are not limited to, methoxy, ethoxy, propoxy, prop-2-oxy, butoxy, but-2-oxy, 2-methylprop-l-oxy, 2-methylprop-2-oxy, pentoxy and hexyloxy.
  • a C 1 4 alkoxy group is one embodiment, for example methoxy, ethoxy, propoxy, prop-2-oxy, butoxy, but-2-oxy or 2-methylprop-2-oxy.
  • hydroxyalkyl refers to a straight or branched hydrocarbon chain containing the specified number of carbon atoms, which is substituted by 1-3 hydroxyl groups.
  • C 1 4 hydroxyalkyl means a straight or branched alkyl chain containing from 1 to 4 carbon atoms and at least one hydroxyl group; examples of such group include hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxyisopropyl, hydroxybutyl and the like.
  • alkenyl as used herein as a group or a part of a group refers to a straight or branched hydrocarbon chain containing the specified number of carbon atoms and containing at least one double bond.
  • C 2 6 alkenyl means a straight or branched alkenyl containing at least 2 and at most 6 carbon atoms and containing at least one double bond.
  • alkenyl examples include, but are not limited to, ethenyl, 2-propenyl, 3- butenyl, 2-butenyl, 2-pentenyl, 3-pentenyl, 3-methyl-2-butenyl, 3-methylbut-2-enyl, 3-hexenyl and l,l-dimethylbut-2-enyl. It will be appreciated that in groups of the form -O-C alkenyl, the double bond is preferably not adjacent to the oxygen.
  • alkynyl as used herein as a group or a part of a group refers to a straight or branched hydrocarbon chain containing the specified number of carbon atoms and containing at least one triple bond.
  • C alkynyl means a straight or branched alkynyl containing at least 2 and at most 6 carbon atoms and containing at least one triple bond.
  • alkynyl examples include, but are not limited to, ethynyl, 2-propynyl, 3- butynyl, 2-butynyl, 2-pentynyl, 3-pentynyl, 3-methyl-2-butynyl, 3-methylbut-2-ynyl, 3- hexynyl and l,l-dimethylbut-2-ynyl. It will be appreciated that in groups of the form -O-C2-6 alkynyl, the triple bond is preferably not adjacent to the oxygen.
  • halo refers to halogens such as fluorine, chlorine, bromine or iodine atoms.
  • sulfuride refers to a radical of R 3 -S-R b , wherein a sulfur atom is covalently attached to two hydrocarbon chains, R 3 and R b , wherein the two hydrocarbon chains may be, for example, but not limited to, any discussed above.
  • the compounds of the invention i.e. those of formula (I), possess antimegakaryocytic activity in humans. They may be particularly useful in the treatment of myeloprolific diseases. The compounds may also find utility in the treatment of generalised thrombotic diseases.
  • references to treatment include prophylaxis as well as the alleviation of established symptoms of a condition.
  • Treating or “treatment” of a state, disorder or condition includes: (1) preventing or delaying the appearance of clinical symptoms of the state, disorder or condition developing in a human that may be afflicted with or predisposed to the state, disorder or condition but does not yet experience or display clinical or subclinical symptoms of the state, disorder or condition, (2) inhibiting the state, disorder or condition, i.e., arresting, reducing or delaying the development of the disease or a relapse thereof (in case of maintenance treatment) or at least one clinical or subclinical symptom thereof, or (3) relieving or attenuating the disease, i. e. , causing regression of the state, disorder or condition or at least one of its clinical or subclinical symptoms.
  • Myeloproliferative diseases which may be treatable with the compounds of the present invention include: essential thrombocythemia, polycythema vera, chronic idiopathic myelofibrosis, chronic myeloid leukaemia with residual thrombocytosis, reactive thrombocytosis immediately preceding a surgical procedures, as an immediate or post operative preventative measures to minimise the risk of thrombus formation during or post surgery.
  • Thrombotic cardiovascular diseases (TCVD) i.e. patients at increased generalised thrombotic risk
  • myocardial infarct heart attack
  • thrombotic stroke patients having undergone coronary stent placement.
  • the compounds of the present invention may find utility for the reduction of atherothrombotic events as follows: recent MI, recent stroke or established peripheral arterial disease, acute coronary syndrome (unstable angina/non-Qwave MI), cardiovascular death, MI, stroke, and refractory ischemia.
  • compounds of formula (I) may contain one or more asymmetric carbon atoms, thus compounds of the invention can exist as two or more stereoisomers.
  • stereoisomers such as enantiomers and diastereomers, all geometric isomers and tautomeric forms of the compounds of formula (I), including compounds exhibiting more than one type of isomerism, and mixtures of one or more thereof.
  • test media were: a) singly distilled water (pH 5.0) - note no attempt was made to remove dissolved CO 2 . b) 50 mM ammonium formate (pH 7.9) c) 0.1 M hydrochloric acid (pH 0.6)
  • Geometric isomers may be separated by conventional techniques well known to those skilled in the art, for example, by chromatography and fractional crystallisation.
  • Stereoisomers may be separated by conventional techniques known to those skilled in the art - see, for example, "Stereochemistry of Organic Compounds” by E L Eliel (Wiley, New York, 1994).
  • the compounds of formula I can be prepared using literature techniques and in an analogous manner to those described in Formula Scheme I and Formula Scheme II in US 4256748.
  • the synthesis of 3 -ethyl anagrelide is described by way of example to show how individual isomers of the invention can be prepared.
  • Analogous procedures can be used to prepare the other compounds of the invention by using appropriate ⁇ -haloesters
  • racemic ⁇ -haloester can be employed in the first stage of the synthesis.
  • compositions of the invention may be administered alone or in combination with one or more other compounds of the invention or in combination with one or more other drugs. Generally, they will be administered as a formulation in association with one or more pharmaceutically acceptable excipients.
  • Pharmaceutically acceptable excipients include one or more of: anti-oxidants, colourants, flavouring agents, preservatives and taste-masking agents.
  • compositions suitable for the delivery of compounds of the present invention and methods for their preparation will be readily apparent to those skilled in the art. Such compositions and methods for their preparation may be found, for example, in 'Remington's Pharmaceutical Sciences', 19th Edition (Mack Publishing Company, 1995). The formulation of tablets is discussed in "Pharmaceutical Dosage Forms: Tablets, Vol. 1", by H. Lieberman and L. Lachman, Marcel Dekker, N. Y., N.Y., 1980 (ISBN 0-8247-6918-X).
  • the methods by which the compounds may be administered include oral administration by capsule, bolus, tablet, powders, lozenges, chews, multi and nanoparticulates, gels, solid solution, films, sprays, or liquid formulation.
  • Liquid forms include suspensions, solutions, and syrups.
  • Such formulations may be employed as fillers in soft or hard capsules and typically comprise a carrier, for example, water, ethanol, polyethylene glycol, propylene glycol, methylcellulose, or a suitable oil, and one or more emulsifying agents and/or suspending agents.
  • a carrier for example, water, ethanol, polyethylene glycol, propylene glycol, methylcellulose, or a suitable oil, and one or more emulsifying agents and/or suspending agents.
  • Liquid formulations may also be prepared by the reconstitution of a solid preparation, for example, from a sachet.
  • the compounds may also be administered topically to the skin or mucosa, that is dermally or transdermally.
  • Typical formulations for this purpose include pour-on solutions, sprays, powder formulations, gels, hydrogels, lotions, creams, ointments, films and patches, and implants.
  • the compounds can also be administered parenterally, or by injection directly into the blood stream, muscle or into an internal organ.
  • Suitable means for parenteral administration include intravenous, intraarterial, intraperitoneal, intrathecal, intraventricular, intraurethral, intrasternal, intracranial, intramuscular and subcutaneous.
  • Suitable devices for parenteral administration include needle (including microneedle) injectors, needle-free injectors and infusion techniques.
  • Formulations may be immediate and/or modified controlled release.
  • Controlled release formulations include Modified release formulations include: delayed-, sustained-, and pulsed- release.
  • a physician will determine the actual dosage which will be most suitable for an individual subject.
  • the specific dose level and frequency of dosage for any particular individual may be varied and will depend upon a variety of factors including the activity of the specific compound employed, the metabolic stability and length of action of that compound, the age, body weight, general health, sex, diet, mode and time of administration, rate of excretion, drug combination, the severity of the particular condition, and the individual undergoing therapy.
  • a suitable dose will be in the range of from about 0.001 to about 50 mg/kg of body weight per day, in a further embodiment, of from about 0.001 to about 5 mg/kg of body weight per day; in a further embodiment of from about 0.001 to about 0.5 mg/kg of body weight per day and in yet a further embodiment of from about 0.001 to about 0.1mg/kg of body weight per day.
  • the ranges can be of from about 0.1 to about 750 mg/kg of body weight per day, in the range of 0.5 to 60 mg/kg/day, and in the range of 1 to 20 mg/kg/day.
  • the desired dose may conveniently be presented in a single dose or as divided doses administered at appropriate intervals, for example as one, two, three, four or more doses per day. If the compounds are administered transdermally or in extended release form, the compounds could be dosed once a day or less.
  • the compound is conveniently administered in unit dosage form; for example containing 0.1 to 50 mg, conveniently 0.1 to 5 mg, most conveniently 0.1 to 5 mg of active ingredient per unit dosage form.
  • the compound can conveniently administered in unit dosage form; for example containing 10 to 1500 mg, 20 to 1000 mg, or 50 to 700 mg of active ingredient per unit dosage form.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Cette invention porte sur la découverte d'analogues substitués en 3 et 5 de l'agent de diminution sélective des plaquettes anagrélide, présentant un potentiel réduit pour des effets secondaires cardio-vasculaires, qui devraient conduire à une compliance améliorée du patient et à une sécurité accrue dans le traitement de maladies myéloprolifératives. Plus spécifiquement, la présente invention porte sur certains dérivés d'imidazoquinazoline qui ont une utilité en tant qu'agents de diminution des plaquettes chez les êtres humains. Les composés de la présente invention agissent par inhibition de la mégakaryocytopoïèse et, de ce fait, de la formation des plaquettes sanguines.
EP07824909A 2006-11-28 2007-11-19 Quinazolines substituées Withdrawn EP2099802A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0623750.7A GB0623750D0 (en) 2006-11-28 2006-11-28 Substituted quinazolines
PCT/GB2007/050697 WO2008065444A2 (fr) 2006-11-28 2007-11-19 Quinazolines substituées

Publications (1)

Publication Number Publication Date
EP2099802A2 true EP2099802A2 (fr) 2009-09-16

Family

ID=37671460

Family Applications (1)

Application Number Title Priority Date Filing Date
EP07824909A Withdrawn EP2099802A2 (fr) 2006-11-28 2007-11-19 Quinazolines substituées

Country Status (14)

Country Link
EP (1) EP2099802A2 (fr)
JP (1) JP2010511030A (fr)
KR (1) KR20090094268A (fr)
CN (1) CN101558071B (fr)
AR (1) AR064002A1 (fr)
AU (1) AU2007327047B2 (fr)
BR (1) BRPI0719570A2 (fr)
CA (1) CA2670123A1 (fr)
EA (1) EA018259B1 (fr)
GB (1) GB0623750D0 (fr)
IL (1) IL198809A0 (fr)
MX (1) MX2009005579A (fr)
TW (1) TW200838537A (fr)
WO (1) WO2008065444A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8304420B2 (en) 2006-11-28 2012-11-06 Shire Llc Substituted quinazolines for reducing platelet count
GB0808944D0 (en) * 2008-05-16 2008-06-25 Shire Llc Substituted quinazolines
GB2462022B (en) 2008-06-16 2011-05-25 Biovascular Inc Controlled release compositions of agents that reduce circulating levels of platelets and methods thereof
GB0822970D0 (en) * 2008-12-17 2009-01-21 Shire Llc Process for the preparation of anagrelide and analogues
GB201004495D0 (en) 2010-03-18 2010-05-05 Shire Llc Subtituted quinazolines
GB201017783D0 (en) 2010-10-21 2010-12-01 Shire Llc Process for the preparation of anagrelide and analogues thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7807507A (nl) * 1977-07-25 1979-01-29 Hoffmann La Roche Tricyclische verbindingen.
CA1131631A (fr) * 1979-06-20 1982-09-14 Madhukar S. Chodnekar Derives de la quinazoline et preparations pharmaceutiques
ZA803535B (en) * 1979-06-20 1981-06-24 Hoffmann La Roche Novel quinazoline derivatives and pharmaceutical preparations
ES2344062T5 (es) * 2003-01-23 2013-04-26 Shire Biopharmaceuticals Holdings Ireland Limited Formulación y procedimientos para el tratamiento de la trombocitopenia
US7700608B2 (en) * 2004-08-04 2010-04-20 Shire Holdings Ag Quinazoline derivatives and their use in the treatment of thrombocythemia
US20060030574A1 (en) * 2004-08-04 2006-02-09 Shire Holdings Ag Quinazoline derivatives useful for the treatment of peripheral arterial disease and as phosphodiesterase inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2008065444A2 *

Also Published As

Publication number Publication date
WO2008065444A3 (fr) 2008-07-31
GB0623750D0 (en) 2007-01-10
BRPI0719570A2 (pt) 2013-12-10
CN101558071B (zh) 2013-04-24
CN101558071A (zh) 2009-10-14
WO2008065444A2 (fr) 2008-06-05
AU2007327047A1 (en) 2008-06-05
EA200900740A1 (ru) 2010-02-26
JP2010511030A (ja) 2010-04-08
IL198809A0 (en) 2010-02-17
CA2670123A1 (fr) 2008-06-05
EA018259B1 (ru) 2013-06-28
TW200838537A (en) 2008-10-01
MX2009005579A (es) 2009-08-12
WO2008065444B1 (fr) 2008-10-09
KR20090094268A (ko) 2009-09-04
AR064002A1 (es) 2009-03-04
AU2007327047B2 (en) 2012-08-30

Similar Documents

Publication Publication Date Title
AU2007327047B2 (en) Substituted quinazolines
EP2297159B1 (fr) Quinazolines substitués
WO2009138794A1 (fr) Dérivés d'imidazoquinazoline en tant qu'analogues d'anagrélide pour le traitement de syndromes myéloprolifératifs et de syndromes thrombotiques
US20110071171A1 (en) 2h- pyrimido [2, 1-b] quinazolin-2-one derivatives and their use as platelet anti-aggregative agents
US20110130405A1 (en) Substituted quinazolines as blood platelet lowering agents
US20110065714A1 (en) Substituted quinazolines
US20110071174A1 (en) Substituted quinazolines
WO2009138790A1 (fr) Quinazolines substituées et leurs utilisations contre les syndromes myéloprolifératifs et thrombotiques
US7910597B2 (en) Substituted quinazolines
AU2009254988A1 (en) Substituted quinazolines
EP2297158A1 (fr) Quinazolines substituées utilisées en tant qu'agents de réduction des plaquettes sanguines

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20090615

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK RS

17Q First examination report despatched

Effective date: 20101027

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20130802